Integration and the risk of liver cancer—Is there a real risk?
Journal of Viral Hepatitis · 2024
DOI: 10.1111/jvh.13915 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Viral Hepatitis, 2024. Verfasst von Aradhana Kasimsetty und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 79 Literaturangaben. Gefördert von: Publication of this Specific Issue is made possible by an educational grant from BioMarin Pharmaceutical..
Abstract (Originalsprache)
Adeno‐associated virus (AAV)‐based gene therapies are in clinical development for haemophilia and other genetic diseases. Since the recombinant AAV genome primarily remains episomal, it provides the opportunity for long‐term expression in tissues that are not proliferating and reduces the safety concerns compared with integrating viral vectors. However, AAV integration events are detected at a low frequency. Preclinical studies in mouse models have reported hepatocellular carcinoma (HCC) after systemic AAV administration in some settings, though this has not been reported in large animal models. The risk of HCC or other cancers after AAV gene therapy in clinical studies thus remains theoretical. Potential risk factors for HCC after gene therapy are beginning to be elucidated through animal studies, but their relevance to human studies remains unknown. Studies to investigate the factors that may influence the risk of oncogenesis as well as detailed investigation of cases of cancer in AAV gene therapy patients will be important to define the potential risk of AAV genotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Division of Hematology, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Denise E Sabatino
Förderung
- Publication of this Specific Issue is made possible by an educational grant from BioMarin Pharmaceutical.
Zitieren
APA
Kasimsetty, A., & Sabatino, D. E. (2024). Integration and the risk of liver cancer—Is there a real risk?. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13915
Vancouver
Kasimsetty A, Sabatino DE. Integration and the risk of liver cancer—Is there a real risk?. Journal of Viral Hepatitis. 2024. doi:10.1111/jvh.13915
BibTeX
@article{Kasimsetty2024,
author = {Kasimsetty, Aradhana and Sabatino, Denise E},
title = {Integration and the risk of liver cancer—Is there a real risk?},
journal = {Journal of Viral Hepatitis},
year = {2024},
doi = {10.1111/jvh.13915}
}
EUVIMED